UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Development of Immunotherapy Combination Strategies in Cancer

Cancer discovery, 2021-06, Vol.11 (6), p.1368-1397

2021

Volltextzugriff (PDF)

cGAS-STING signalling in cancer: striking a balance with chromosomal instability

Biochemical Society transactions, 2023-04, Vol.51 (2), p.539-555

2023

Volltextzugriff (PDF)

Targeting mitotic regulators in cancer as a strategy to enhance immune recognition

DNA repair, 2023-12, Vol.132, p.103583-103583, Article 103583

2023

Volltextzugriff (PDF)

The clinical and molecular significance associated with STING signaling in breast cancer

NPJ breast cancer, 2021-06, Vol.7 (1), p.81-81, Article 81

2021

Volltextzugriff (PDF)

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

JNCI : Journal of the National Cancer Institute, 2017-01, Vol.109 (1), p.djw199

2017

Volltextzugriff (PDF)

Non-cell-autonomous cancer progression from chromosomal instability

Nature (London), 2023-08, Vol.620 (7976), p.1080-1088

2023

Volltextzugriff (PDF)

Clinical Application of Poly(ADP‐Ribose) Polymerase Inhibitors in High‐Grade Serous Ovarian Cancer

The oncologist (Dayton, Ohio), 2016-05, Vol.21 (5), p.586-593

2016

Volltextzugriff (PDF)

Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model

British journal of cancer, 2020-09, Vol.123 (7), p.1089-1100

2020

Volltextzugriff (PDF)

DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy

Journal of oncology, 2019-01, Vol.2019 (2019), p.1-14

2019

Volltextzugriff (PDF)

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial

Journal of clinical oncology, 2019-12, Vol.37 (36), p.3484-3492

2019

Volltextzugriff (PDF)

When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers

Trends in Cancer, 2022-03, Vol.8 (3), p.174-189

2022

Volltextzugriff (PDF)

Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

British journal of cancer, 2022-02, Vol.126 (2), p.247-258

2022

Volltextzugriff (PDF)

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer

British journal of cancer, 2021-02, Vol.124 (3), p.581-586

2021

Volltextzugriff (PDF)

Reactivation of low avidity tumor-specific CD8 + T cells associates with immunotherapeutic efficacy of anti-PD-1

Journal for immunotherapy of cancer, 2023-08, Vol.11 (8), p.e007114

2023

Volltextzugriff (PDF)

Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer

Journal of oncology, 2018-01, Vol.2018 (2018), p.1-14

2018

Volltextzugriff (PDF)

Abstract 4000: A DNA damage response deficiency (DDRD) group in breast cancer is associated with activation of the STING innate immune pathway and PD-L1 expression

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.4000-4000

2016

Volltextzugriff (PDF)

NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS2682-TPS2682

2022

Volltextzugriff (PDF)

Abstract 3787: Exploring the effect of chemotherapies on STING-dependent cytokine release

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.3787-3787

2018

Volltextzugriff (PDF)

A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS3637-TPS3637

2022

Volltextzugriff (PDF)

Abstract 2704: cGAS-STING drives myeloid inflammation in chromosomally unstable esophageal cancer

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.2704-2704

2024

Volltextzugriff (PDF)

Abstract 6406: Radiation and STING activation limit tumor development and modulate the immune environment via distinct mechanisms

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.6406-6406

2023

Volltextzugriff (PDF)

Consensus gene expression analysis to identify key hallmarks of cancer in malignant melanoma

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e21045-e21045

2019

Volltextzugriff (PDF)

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway

Molecular cancer, 2023-08, Vol.22 (1), p.133-25, Article 133

2023

Volltextzugriff (PDF)

Abstract P1-10-17: cGAS-STING driven immune activation predicts response to neoadjuvant chemotherapy and suggests rational IO combination therapies: Results of the Neo-DDIR study

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P1-P1-10-17

2020

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Development of Immunotherapy Combination Strategies in Cancer

cGAS-STING signalling in cancer: striking a balance with chromosomal instability

Targeting mitotic regulators in cancer as a strategy to enhance immune recognition

The clinical and molecular significance associated with STING signaling in breast cancer

Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer

Non-cell-autonomous cancer progression from chromosomal instability

Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis

Clinical Application of Poly(ADP‐Ribose) Polymerase Inhibitors in High‐Grade Serous Ovarian Cancer

Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model

DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy

Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial

When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers

Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer

Reactivation of low avidity tumor-specific CD8 + T cells associates with immunotherapeutic efficacy of anti-PD-1

Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer

Abstract 4000: A DNA damage response deficiency (DDRD) group in breast cancer is associated with activation of the STING innate immune pathway and PD-L1 expression

NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors

Abstract 3787: Exploring the effect of chemotherapies on STING-dependent cytokine release

A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments

Abstract 2704: cGAS-STING drives myeloid inflammation in chromosomally unstable esophageal cancer

Abstract 6406: Radiation and STING activation limit tumor development and modulate the immune environment via distinct mechanisms

Consensus gene expression analysis to identify key hallmarks of cancer in malignant melanoma

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway

Abstract P1-10-17: cGAS-STING driven immune activation predicts response to neoadjuvant chemotherapy and suggests rational IO combination therapies: Results of the Neo-DDIR study

Suchergebnisse filtern